13F Holdings
中文EN

RLMD RELMADA THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1553643 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-16.9%
TTM EPS YoY59.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-64.7%
ROA-59.7%
ROIC (approx.)-54.7%
Asset turnover—

Leverage & solvency

Liabilities / assets5.6%
Debt / equity0.00x
Current ratio26.37x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-12.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$26.88M$46.18M$54.81M$113.32M$90.62M
SG&A expense$32.22M$37.72M$48.89M$47.93M$35.08M
Operating income-$59.10M-$83.89M-$103.70M-$161.25M-$125.70M
Net income-$57.39M-$79.98M-$98.79M-$157.04M-$125.75M
EBITDA————-$125.70M
EPS (basic)-1.45-2.65-3.28-5.30-7.16
EPS (diluted)-1.45-2.65-3.28-5.30-7.16
Weighted avg. shares (diluted)39.48M30.16M30.10M29.63M17.55M
Banking
Net interest income——$5.15M$2.66M$1.20M
Balance sheet
Cash & equivalents$3.50M$3.86M$4.09M$5.40M$44.44M
Short-term investments$89.51M$41.05M$92.23M$142.93M$167.47M
Receivables———$512,432—
Current assets$93.98M$45.80M$97.51M$152.87M$223.30M
Total assets$94.00M$45.82M$97.55M$152.91M$223.33M
Current liabilities$6.43M$10.29M$12.19M$12.47M$15.06M
Total liabilities$7.49M$10.30M$12.19M$12.47M$15.06M
Shareholders' equity$86.51M$35.52M$85.36M$140.44M$208.26M
Shares outstanding73.33M30.17M30.10M30.10M27.74M
Cash flow statement
Operating cash flow-$45.79M-$51.76M-$51.66M-$103.80M-$91.87M
Investing cash flow-$48.14M$51.56M$50.45M$19.73M-$54.12M
Financing cash flow$93.56M-$40,341-$98,463$45.02M$187.94M
Depreciation & amortization————$1,258
Stock-based compensation$13.91M$30.18M$43.81M$44.19M$40.49M

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.